Q3 Earnings Estimate for ARCT Issued By Leerink Partnrs

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) – Equities research analysts at Leerink Partnrs issued their Q3 2025 earnings per share estimates for shares of Arcturus Therapeutics in a report issued on Wednesday, January 22nd. Leerink Partnrs analyst L. Nsongo expects that the biotechnology company will earn ($0.80) per share for the quarter. The consensus estimate for Arcturus Therapeutics’ current full-year earnings is ($2.31) per share.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.44. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. The firm had revenue of $41.67 million during the quarter, compared to analyst estimates of $49.16 million. During the same period last year, the company earned ($0.61) earnings per share.

ARCT has been the subject of a number of other reports. Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a report on Monday, December 16th. HC Wainwright restated a “buy” rating and set a $63.00 price target on shares of Arcturus Therapeutics in a research report on Monday, January 13th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Arcturus Therapeutics presently has an average rating of “Buy” and an average target price of $66.75.

Arcturus Therapeutics Stock Up 4.1 %

Shares of ARCT stock opened at $17.42 on Thursday. The business has a 50-day moving average price of $17.27 and a two-hundred day moving average price of $19.74. Arcturus Therapeutics has a 12-month low of $14.30 and a 12-month high of $45.00. The firm has a market cap of $471.91 million, a P/E ratio of -7.85 and a beta of 2.63.

Institutional Trading of Arcturus Therapeutics

Institutional investors have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Arcturus Therapeutics by 10.8% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,694 shares of the biotechnology company’s stock valued at $202,000 after purchasing an additional 846 shares during the last quarter. nVerses Capital LLC bought a new position in shares of Arcturus Therapeutics during the third quarter valued at approximately $42,000. China Universal Asset Management Co. Ltd. lifted its stake in Arcturus Therapeutics by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company’s stock worth $121,000 after acquiring an additional 2,038 shares during the period. Nordea Investment Management AB boosted its holdings in Arcturus Therapeutics by 3.7% in the fourth quarter. Nordea Investment Management AB now owns 65,778 shares of the biotechnology company’s stock valued at $1,097,000 after acquiring an additional 2,335 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in Arcturus Therapeutics by 1.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 197,622 shares of the biotechnology company’s stock valued at $4,587,000 after purchasing an additional 3,224 shares during the period. 94.54% of the stock is currently owned by hedge funds and other institutional investors.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.